These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
511 related articles for article (PubMed ID: 34782447)
1. Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Autoimmune Conditions Treated With Systemic Therapies: A Population-based Study. Curtis JR; Zhou X; Rubin DT; Reinisch W; Yazdany J; Robinson PC; Chen Y; Benda B; Madsen A; Geier J J Rheumatol; 2022 Mar; 49(3):320-329. PubMed ID: 34782447 [TBL] [Abstract][Full Text] [Related]
2. Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States. Raiker R; DeYoung C; Pakhchanian H; Ahmed S; Kavadichanda C; Gupta L; Kardeş S Semin Arthritis Rheum; 2021 Oct; 51(5):1057-1066. PubMed ID: 34450504 [TBL] [Abstract][Full Text] [Related]
3. Factors Associated with Severe COVID-19 Among Patients with Rheumatoid Arthritis: A Large, Nationwide Electronic Health Record Cohort Study in the United States. Ye Y; Yue X; Krueger WS; Wegrzyn LR; Maniccia AW; Winthrop KL; Kim SC Adv Ther; 2023 Sep; 40(9):3723-3738. PubMed ID: 37338653 [TBL] [Abstract][Full Text] [Related]
4. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs). Paul D; Patil D; McDonald L; Patel V; Lobo F J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547 [No Abstract] [Full Text] [Related]
5. Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark. Cordtz R; Lindhardsen J; Soussi BG; Vela J; Uhrenholt L; Westermann R; Kristensen S; Nielsen H; Torp-Pedersen C; Dreyer L Rheumatology (Oxford); 2021 Oct; 60(SI):SI59-SI67. PubMed ID: 33369663 [TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study. Kridin K; Schonmann Y; Damiani G; Peretz A; Onn E; Bitan DT; Cohen AD Dermatol Ther; 2021 Jul; 34(4):e15003. PubMed ID: 34033207 [TBL] [Abstract][Full Text] [Related]
7. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Ljung L; Askling J; Rantapää-Dahlqvist S; Jacobsson L; Arthritis Res Ther; 2014 Jun; 16(3):R127. PubMed ID: 24941916 [TBL] [Abstract][Full Text] [Related]
8. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Low AS; Symmons DP; Lunt M; Mercer LK; Gale CP; Watson KD; Dixon WG; Hyrich KL; Ann Rheum Dis; 2017 Apr; 76(4):654-660. PubMed ID: 28073800 [TBL] [Abstract][Full Text] [Related]
9. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. Hellgren K; Smedby KE; Backlin C; Sundstrom C; Feltelius N; Eriksson JK; Baecklund E; Askling J Arthritis Rheumatol; 2014 May; 66(5):1282-90. PubMed ID: 24782185 [TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis to describe associations between tumor necrosis factor alpha inhibitors and COPD-related hospitalizations. Accortt NA; Chung JB; Bonafede M; Limone BL; Mannino DM Int J Chron Obstruct Pulmon Dis; 2017; 12():2085-2094. PubMed ID: 28790811 [TBL] [Abstract][Full Text] [Related]
11. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153 [TBL] [Abstract][Full Text] [Related]
12. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis. Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724 [TBL] [Abstract][Full Text] [Related]
13. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden. Wadström H; Frisell T; Askling J; JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211 [TBL] [Abstract][Full Text] [Related]
14. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265 [TBL] [Abstract][Full Text] [Related]
15. The Association between Noninfectious Uveitis and Coronavirus Disease 2019 Outcomes: An Analysis of United States Claims-Based Data. Miller DC; Sun Y; Chen EM; Arnold BF; Acharya NR Ophthalmology; 2022 Mar; 129(3):334-343. PubMed ID: 34648828 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769 [TBL] [Abstract][Full Text] [Related]